221 related articles for article (PubMed ID: 20132185)
1. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.
Mattioli E; Vogiatzi P; Sun A; Abbadessa G; Angeloni G; D'Ugo D; Trani D; Gaughan JP; Vecchio FM; Cevenini G; Persiani R; Giordano A; Claudio PP
J Cell Physiol; 2007 Jan; 210(1):183-91. PubMed ID: 16998811
[TBL] [Abstract][Full Text] [Related]
3. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
Fang J; Zhang M; Li Q
Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
[TBL] [Abstract][Full Text] [Related]
5. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
6. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
7. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
Fujii S; Ochiai A
Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
10. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
11. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma.
Vékony H; Raaphorst FM; Otte AP; van Lohuizen M; Leemans CR; van der Waal I; Bloemena E
J Clin Pathol; 2008 Jun; 61(6):744-9. PubMed ID: 18326020
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
Ougolkov AV; Bilim VN; Billadeau DD
Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
16. TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer.
Fu HL; Ma Y; Lu LG; Hou P; Li BJ; Jin WL; Cui DX
J Biomed Nanotechnol; 2014 Jul; 10(7):1217-30. PubMed ID: 24804542
[TBL] [Abstract][Full Text] [Related]
17. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
18. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines.
Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB
Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941
[TBL] [Abstract][Full Text] [Related]
19. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
[TBL] [Abstract][Full Text] [Related]
20. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA
J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
